MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP
* Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases
* First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy of MC2-25 Cream in Chronic Kidney Disease-associated Pruritus (CKD-aP) stages 3-5 patients
* MC2-25 Cream has the potential to become the first approved treatment for ~30 million people in US and EU with chronic kidney disease associated pruritus stages 3 and 4
* Topline results are expected in Q1 2024
MC2!-->…